News
The addition of talazoparib to enzalutamide extended OS among men with metastatic castration-resistant prostate cancer, according to the agent’s manufacturer.Talazoparib (Talzenna, Pfizer) is an ...
Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer. Feb. 13, 2025 10:00 AM ET Pfizer Inc. (PFE), PFE:CA.
(RTTNews) - Pfizer Inc. (PFE) Thursday reported positive topline results from the Phase 3 TALAPRO-2 study of Talzenna in combination with Xtandi in patients with metastatic castration-resistant ...
Pfizer (PFE) reported positive results from a Phase 3 study of Talzenna in combination with Xtandi in the treatment of certain patients with prostate cancer. Read more here.
Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS gain in HRR-mutated cases.
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA ® (talazoparib), an oral poly ADP ...
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...
Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA ®, an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI ®, an androgen receptor ...
Pfizer Inc. today announced positive topline results from the final prespecified overall survival analysis of the TALAPRO-2 study of TALZENNA ®, an oral poly ADP-ribose polymerase inhibitor, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results